Form 13-F position report

CYMABAY THERAPEUTICS INC

Reported by Altium Capital Management LP

CBAY CUSIP 23257D103 Manager CIK 0001746382

Reported 800,000 shares, up 131,298 (19.6%) from the prior quarter.

Reported value 62.9%; share count 19.6% vs. the prior quarter.

Added
% of reported 13F value 6.22% This manager · Q3 2023
Shares 800,000 Quarter-end amount reported
Reported value $11,928,000 Fair value at quarter end
Consecutive quarters held 8 Through Q3 2023

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2021-12-31 5915000
2022-03-31 5443000
2022-06-30 5163000
2022-09-30 6125000
2022-12-31 6426750
2023-03-31 5406400
2023-06-30 7322287
2023-09-30 11928000
2023-12-31 2621820
2024-03-31 0

Quarterly position history

How this manager's reported quarter-end position changed over time.

10 quarters
Quarterly reported position history for CYMABAY THERAPEUTICS INC held by Altium Capital Management LP.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q1 2024 Reduced 0 -111,000 (-100.0%) 0 $0 2024-05-15
Q4 2023 Reduced 111,000 -689,000 (-86.1%) 1.78% $2,621,820 2024-02-14
Q3 2023 Added 800,000 +131,298 (19.6%) 6.22% $11,928,000 2023-11-14
Q2 2023 Added 668,702 +48,702 (7.9%) 5.54% $7,322,287 2023-08-14
Q1 2023 Reduced 620,000 -405,000 (-39.5%) 3.0% $5,406,400 2023-05-15
Q4 2022 Reduced 1,025,000 -725,000 (-41.4%) 3.27% $6,426,750 2023-02-14
Q3 2022 Unchanged 1,750,000 0 (0.0%) 2.25% $6,125,000 2022-11-14
Q2 2022 Unchanged 1,750,000 0 (0.0%) 2.07% $5,163,000 2022-08-15
Q1 2022 Unchanged 1,750,000 0 (0.0%) 1.82% $5,443,000 2022-05-16
Q4 2021 New 1,750,000 +1,750,000 (0.0%) 1.63% $5,915,000 2022-02-14

Who else reported the position

214 managers reported CYMABAY THERAPEUTICS INC for Q3 2023.

Managers reporting CYMABAY THERAPEUTICS INC in Q3 2023.
Manager Activity Shares Change % of reported 13F Reported value Tenure
Avoro Capital Advisors LLC Unchanged 10,300,000 0 2.4% $153,573,000 19 qtrs
BlackRock Inc Added 7,791,996 +287,326 < 0.01% $116,178,662 27 qtrs
RA CAPITAL MANAGEMENT L P New 6,940,000 +6,940,000 2.04% $103,475,400 1 qtr
JANUS HENDERSON GROUP PLC Reduced 6,803,484 -943,103 0.07% $101,432,021 4 qtrs
VANGUARD GROUP INC Added 5,747,587 +598,707 < 0.01% $85,696,522 37 qtrs
ADAGE CAPITAL PARTNERS GP L L C Reduced 4,125,000 -276,292 0.14% $61,503,750 36 qtrs
PERCEPTIVE ADVISORS LLC Added 4,043,191 +309,936 2.01% $60,283,978 4 qtrs
Cormorant Asset Management LP Added 3,850,000 +50,000 3.35% $57,403,500 3 qtrs
JENNISON ASSOCIATES LLC Added 3,555,274 +1,883,742 0.05% $53,009,135 3 qtrs
FRANKLIN RESOURCES INC Added 3,307,915 +35,907 0.03% $49,321,016 25 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
September 30, 2023
Filed
November 14, 2023
Filing type
13F-HR
Position type
COM

Voting authority reported

Sole
800,000
Shared
0
None
0

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.